Oncogenic signaling pathways in pancreatic ductal adenocarcinoma

Rahul Agrawal, Kedar Nath Natarajan*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingBook chapterResearchpeer-review


Pancreatic ductal adenocarcinoma (PDAC) is the most common (∼90% cases) pancreatic neoplasm and one of the most lethal cancer among all malignances. PDAC harbor aberrant oncogenic signaling that may result from the multiple genetic and epigenetic alterations such as the mutation in driver genes (KRAS, CDKN2A, p53), genomic amplification of regulatory genes (MYC, IGF2BP2, ROIK3), deregulation of chromatin-modifying proteins (HDAC, WDR5) among others. A key event is the formation of Pancreatic Intraepithelial Neoplasia (PanIN) that often results from the activating mutation in KRAS. Mutated KRAS can direct a variety of signaling pathways and modulate downstream targets including MYC,which play an important role in cancer progression. In this review, we discuss recent literature shedding light on the origins of PDAC from the perspective of major oncogenic signaling pathways. We highlight how MYC directly and indirectly, with cooperation with KRAS, affect epigenetic reprogramming and metastasis. Additionally, we summarize the recent findings from single cell genomic approaches that highlight heterogeneity in PDAC and tumor microenvironment, and provide molecular avenues for PDAC treatment in the future.
Original languageEnglish
Title of host publicationPancreatic Cancer: Basic Mechanisms and Therapies
Number of pages33
Publication date2023
ISBN (Electronic)978-0-443-13354-1
Publication statusPublished - 2023
SeriesAdvances in Cancer Research


Dive into the research topics of 'Oncogenic signaling pathways in pancreatic ductal adenocarcinoma'. Together they form a unique fingerprint.

Cite this